Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7871772 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL7774471 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL7860524 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL5615669 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL21060940 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL31112385 | 1.00 | NAAA (0.50) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL27572350 | 0.98 | NAAA (0.48) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL10662861 | 0.98 | NAAA (0.47) | NAAAEPHX1TSHRHCAR2RAD52 | |
| SCHEMBL3405733 | 0.92 | ALDH1A1 (0.48) | NAAAEPHX1TSHRHCAR2LMNA | |
| SCHEMBL31112146 | 0.86 | NAAA (0.47) | NAAAEPHX1TSHRHCAR2RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4705289-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | Terran Biosciences Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| WO-2024226691-A1 | PRODRUGS OF XANOMELINE, PRODRUGS OF TROSPIUM AND METHODS OF USE THEREOF | TERRAN BIOSCIENCES INC. (US) | 2024-10-31 | — | — | WO | disclosed |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| EP-3532057-B1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARM INC (US) | 2022-12-21 | — | — | EP | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2021-07-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| EP-3532057-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2019-09-04 | — | — | EP | disclosed |
| WO-2018081513-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2018-05-03 | — | — | WO | disclosed |
| WO-1997021712-A1 | CARBAPENEM-3-CARBOXYLIC ACID ESTER DERIVATIVES | LEDERLE (JAPAN), LTD. (JP) | 1997-06-19 | — | — | WO | disclosed |
| US-5559266-A | Iodinated esters | NYCOMED IMAGING AS (NO) | 1996-09-24 | — | — | US | disclosed |
| US-5416223-A | Iodinated esters | NYCOMED IMAGING AS (NO) | 1995-05-16 | — | — | US | disclosed |
| US-5370861-A | Iodinated esters contrast medium and use | NYCOMED IMAGING AS (NO) | 1994-12-06 | — | — | US | disclosed |
| EP-0452377-B1 | IODINATED ESTERS | NYCOMED IMAGING AS (NO) | 1994-09-21 | — | — | EP | disclosed |
| EP-0452377-A1 | IODINATED ESTERS. | HOLMES MICHAEL JOHN (GB) | 1991-10-23 | — | — | EP | disclosed |
| WO-1990007491-A1 | IODINATED ESTERS | NYCOMED AS (NO) | 1990-07-12 | — | — | WO | disclosed |
| EP-0147177-B1 | ETHER PRODRUGS OF ANTI-INFLAMMATORY OXICAMS | PFIZER INC. (US) | 1987-10-14 | — | — | EP | disclosed |
| US-4551452-A | Anti-inflammatory 2-methyl-2H-1,2-benzo-(or -thieno-)thiazine-3-carboxamide 1,1-dioxide derivatives, compositions, and method of use therefor | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0147177-A2 | Ether prodrugs of anti-inflammatory oxicams | PFIZER INC. (US) | 1985-07-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210198204-A1 | PRODRUGS OF KALLIKREIN INHIBITORS | KLKB1, SERPINB1, KLK1 | NAAA 340/4885EPHX1 168/4885TSHR 4209/4885 |
| US-11618731-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | NAAA 340/4885EPHX1 168/4885TSHR 4209/4885 |
| US-10759759-B2 | Prodrugs of kallikrein inhibitors | KLKB1, SERPINB1, KLK1 | NAAA 340/4885EPHX1 168/4885TSHR 4209/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.